

Effective: July 1, 2025

<b>Prior Authorization Required</b> If <u>REQUIRED</u> , submit supporting clinical documentation pertinent to service request.	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
--	---

**Applies to:**

- CarePartners of Connecticut Medicare Advantage HMO plans, Fax 617-673-0956
- CarePartners of Connecticut Medicare Advantage PPO plans, Fax 617-673-0956

**Note:** While you may not be the provider responsible for obtaining prior authorization, as a condition of payment you will need to ensure that prior authorization has been obtained.

**Overview**

Chimeric antigen receptor T-cell therapy (CAR-T cell therapy), a type of immunotherapy which may also be referred to as adoptive T-cell therapy, attempts to program patients' own immune systems to recognize and attack cancer cells. The first step in this therapy is to remove T-cells from the patient via apheresis, a process that removes blood from the body and removes one or more blood components (such as white blood cells, plasma, or platelets). The remaining blood is then returned to the body. The T-cells are then sent to a drug manufacturing facility or laboratory where they are genetically engineered to produce chimeric antigen receptors (CARs) on their surface. These CARs are what allow the T-cells to recognize an antigen on targeted tumor cells. The genetically modified T-cells are grown in the lab until there are enough of them (many millions) to freeze and return to the center treating the patient. There they are infused into the recipient with the expectation that the CAR T cells will recognize and kill cancerous cells that have the targeted antigen on their surface. Since the CART cells may remain in the body long after the infusion, it is possible the treatment can bring about long-term remission. CART cell therapy can be used to treat certain hematologic malignancies when the disease is relapsed or refractory to standard line(s) of treatment.

**Food and Drug Administration (FDA) Approved Indications:**

- AUCATZYL is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

The Plan uses guidance from the Centers for Medicare and Medicaid Services (CMS) and MassHealth for coverage determinations for its Dual Product Eligible plan members, and Centers for Medicare and Medicaid Services (CMS) for coverage determinations for its Medicare Advantage plan members. CMS National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), Local Coverage Articles (LCAs) and documentation included in the Medicare manuals and MassHealth Medical Necessity Determinations are the basis for coverage determinations where available. For the Plan's members, the following criteria is used: [Chimeric Antigen Receptor \(CAR\) T- cell Therapy NCD 110.24](#)

**Clinical Guideline Coverage Criteria**

The Plan may cover Aucatzyl when all the following clinical criteria is met:

1. The Member has a diagnosis of B-cell precursor acute lymphoblastic leukemia (ALL); **AND**
2. The Member is ≥ 18 years of age on treatment date; **AND**
3. The Member has not received prior treatment with a CAR-T therapy; **AND**

In addition to the above criteria, the Plan may cover Aucatzyl in an outpatient setting when all of the following criteria is met:

1. The provider attests that they have assessed the Member and determined that outpatient administration is clinically appropriate.

**AND**

2. The provider attests that the Member meets and understands the requirements of safety and monitoring post infusion.

**Note:** Prior authorization for Aucatzyl is required regardless of hospital inpatient or outpatient setting.

---

## Limitations

- Members who have had prior treatment with any form of CAR-T cell therapy, including therapies in clinical trial settings, will not be approved for additional CAR-T therapy.
- Authorization for Aucatzyl is limited to a one-time infusion
- All other indications other than those listed above are considered experimental/investigational and not medically necessary.

---

## Codes

The following code(s) require prior authorization:

**Table 1: HCPCS Codes**

HCPCS Codes	Description
Q2058	Obecabtagene Autoleucel, 10 Up To 400 Million CD19 CAR-Positive Viable T Cells, Including Leukapheresis And Dose Preparation Procedures, Per Infusion

## References:

1. National Comprehensive Cancer Network. Acute Lymphoblastic Leukemia (Version 3.2024) [https://www.nccn.org/professionals/physician\\_gls/pdf/all.pdf](https://www.nccn.org/professionals/physician_gls/pdf/all.pdf) accessed January 17, 2025.
2. Center for Medicare and Medicaid National Coverage Determination (NCD) for Chimeric Antigen Receptor (CAR) T-cell Therapy. <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=374&bc=CAAAAAAAAAAAAA>.
3. Aucatzyl® [package insert]. Gaithersburg (MD): Autolus Inc.; November 2024.
4. Roddie C, Sandhu K, et. al. S262: Safety And Efficacy Of Obecabtagene Autoleucel (Obe-Cel), A Fast-Off Rate Cd19 Car In Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukaemia: Top Line Results Of The Pivotal Felix Study. *Hemasphere*. 2023 Aug 8;7(Suppl ):e998506d. doi: 10.1097/01.HS9.0000967960.99850.6d. PMID: PMC10428320.

---

## Approval And Revision History

February 19, 2025: Reviewed by the Medical Policy Approval Committee (MPAC), effective April 1, 2025

Subsequent dates and changes made:.

- May 13, 2025: Coding updated per AMA HCPCS, replaced C9301 with Q2058, effective July 1, 2025.

---

## Background, Product and Disclaimer Information

Medical Necessity Guidelines are developed to determine coverage for benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. We make coverage decisions using these guidelines, along with the Member's benefit document, and in coordination with the Member's physician(s) on a case-by-case basis considering the individual Member's health care needs.

Medical Necessity Guidelines are developed for selected therapeutic or diagnostic services found to be safe and proven effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in our service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. We revise and update Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

Treating providers are solely responsible for the medical advice and treatment of Members. The use of this guideline is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to eligibility and benefits on the date of service, coordination of benefits, referral/authorization, utilization management guidelines when applicable, and adherence to plan policies, plan procedures, and claims editing logic.